The Income Tax Board of Review has dismissed an appeal by a medical practitioner (identified as GIP) against the Inland Revenue Authority of Singapore’s (IRAS) application of the general anti-avoidance provision (Section 33 of the Income Tax Act). The ruling reinforces the Comptroller of Income Tax’s power to counter arrangements primarily designed to reduce tax liability.
Background of the Case:
The taxpayer served as deputy medical director at a major medical service provider (NRM) until 2011. In July 2011, he entered into a partnership with GBRN (a wholly-owned subsidiary of NRM) to operate a clinic. On 18 February 2012, he incorporated FDP Pte Ltd, becoming its sole shareholder and director. Shortly thereafter, FDP replaced the taxpayer as GBRN’s partner in the clinic business.
IRAS Audit and Assessment:
Following an audit commencing in February 2016, IRAS determined that the income reported by FDP for Years of Assessment (YA) 2013 to 2016 actually stemmed from medical and consultation services personally rendered by the taxpayer to the clinic. Key findings included:
- No Operational Change: The taxpayer remained the sole key service provider before and after FDP’s incorporation.
- Artificially Low Remuneration: The taxpayer received only $85,000 annually in director’s fees from FDP, deemed disproportionately low compared to the clinic’s income derived from his services.
Consequently, the Comptroller invoked Section 33(1) to disregard the arrangement, attributing the clinic’s full service income directly to the taxpayer. This resulted in additional income tax assessments totalling $128,475.86 for YA 2013 to YA 2018.
Board of Review’s Decision & Key Findings:
The taxpayer appealed, contesting the validity of the Section 33(1) invocation. The Board dismissed the appeal, upholding the Comptroller’s position based on these critical conclusions:
- Tax Avoidance Purpose Established (s 33(1)(c)): The Board agreed the arrangement’s net effect enabled the taxpayer to access clinic revenue equivalent to personal income while paying substantially less personal income tax. Section 33(1)(c)’s test was satisfied.
- Bona Fide Commercial Purpose Lacking (s 33(3)(b)): The taxpayer claimed FDP was incorporated for limited liability protection against potential medical, public, and commercial claims. However, the Board found no evidence submitted substantiated this claim or demonstrated it was a main purpose outweighing tax avoidance.
- Tax Exemptions Inapplicable: The taxpayer failed to prove the tax advantage obtained fell within the purpose of the Partial Tax Exemption (s 43(6A)) or Start-up Tax Exemption (s 43(6C)) schemes.
- Comptroller’s Exercise of Power Reasonable: The Board found the Comptroller’s application of Section 33 and the resulting assessment was fair and reasonable in the circumstances.
Implications:
The GIP v Comptroller of Income Tax [2024] SGITBR 2 decision underscores IRAS’s vigilance and the Board’s support in applying Section 33 against structures lacking genuine commercial substance, particularly where:
- Individuals incorporate entities but continue identical roles.
- Remuneration paid to the individual is artificially low compared to income generated.
- The primary discernible effect is significant personal income tax reduction.
Professionals and businesses utilizing corporate structures must ensure arrangements are driven by bona fide commercial reasons and adequately documented, not primarily tax reduction.
Key Takeaways Box:
| Aspect | Finding | Implication |
|---|---|---|
| Core Issue | Validity of Section 33 GAAR application | IRAS can disregard artificial structures |
| Taxpayer’s Structure | Services via owned company (FDP) after partnership | Deemed ineffective for income splitting |
| IRAS Assessment | Full clinic income attributed to doctor | Additional tax: $128,475.86 (YA13-18) |
| Bona Fide Defense | Limited liability claim rejected | Insufficient evidence of commercial purpose |
| Appeal Outcome | Dismissed | GAAR application upheld by Board |
Source: GIP v Comptroller of Income Tax [2024] SGITBR 2 (Decision Date: 2 May 2024)